Systemic lupus erythematosus--2005 annus mirabilis? (Q36577432)

15 August 2017

1 reference

title

Systemic lupus erythematosus--2005 annus mirabilis? (English)

1 reference

systemic lupus erythematosus

15 August 2017

0 references

1

David Isenberg

1 reference

15 August 2017

Anisur Rahman

2

1 reference

15 August 2017

1 March 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

3

1 reference

15 August 2017

145-152

1 reference

Plaquenil in the treatment of lupus erythematosus

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Novel therapies in lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Major peptide autoepitopes for nucleosome-specific T cells of human lupus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Management of lupus erythematosus: recent insights

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Block and tackle: CTLA4Ig takes on lupus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Treatment of murine lupus with CTLA4Ig

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Systemic lupus erythematosus and the type I interferon system

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

BLyS antagonists and peptide tolerance induction

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

A therapeutic role for BLyS antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Complement deficiency and immune complex disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Dehydroepiandrosterone for the treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Autologous stem cell transplantation for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: relation of cytokine pattern to disease duration

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0116

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0116

1 reference

15 August 2017

1 reference

PubMed ID

16932674